Back to Search
Start Over
Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results
- Source :
- Journal of Clinical Oncology. 36:4560-4560
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- 4560Background: Lenvatinib, a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors and other targets, has been approved in combination with everolimus to treat advanced rena...
- Subjects :
- 0301 basic medicine
Cancer Research
Everolimus
biology
business.industry
VEGF receptors
Pembrolizumab
medicine.disease
Vascular endothelial growth factor
03 medical and health sciences
chemistry.chemical_compound
030104 developmental biology
0302 clinical medicine
Oncology
chemistry
Renal cell carcinoma
030220 oncology & carcinogenesis
Cancer research
biology.protein
Medicine
In patient
Lenvatinib
business
Receptor
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........f988d968b414a83b2b298cd45ba816d2
- Full Text :
- https://doi.org/10.1200/jco.2018.36.15_suppl.4560